HCID 15557340, compound → HCID 15557341, compound

HRID 267800Notes

Reaction equation

HRID 267800 reaction equation
[CH:1]([N:4]1[CH2:8][C:7]2([CH2:14][O:13][C:12]3[CH:15]=[CH:16][C:17]([N+:19]([O-])=O)=[CH:18][C:11]=3[O:10][CH2:9]2)[O:6][CH:5]1[C:22]1[CH:27]=[CH:26][CH:25]=[CH:24][CH:23]=1)([CH3:3])[CH3:2].[H][H]>C(OCC)(=O)C.[Pd]>[NH2:19][C:17]1[CH:16]=[CH:15][C:12]2[O:13][CH2:14][C:7]3([CH2:9][O:10][C:11]=2[CH:18]=1)[O:6][CH:5]([C:22]1[CH:23]=[CH:24][CH:25]=[CH:26][CH:27]=1)[N:4]([CH:1]([CH3:2])[CH3:3])[CH2:8]3

Participants

5

Reactant 2

HCID 15557340HCID 15557340, compoundHCID 178418361HCID 178418361, compound

Product 1

HCID 15557341HCID 15557341, compound

Reagents, catalysts & solvents 2

HCID 23938PalladiumCatalystHCID 8857Ethyl AcetateSolvent

Procedure

3'-isopropyl-7-nitro-2'-phenyl-3,4-dihydro-2H-1,5-benzodioxepin-3-spiro-5'-oxazolidine (370 mg.; 1 mmole) in ethyl acetate (10 ml.) is hydrogenated at room temperature and pressure in the presence of 5% palladium on charcoal (50 mg.). When 3 moles of hydrogen has been absorbed (73 ml. at 23° C.) the catalyst is filtered off and the filtrate evaporated to a solid foam; yield 340 mg. (100%). Because of the lability of this compound, it is used in the next stage without purification.

Workup

  1. customis hydrogenated at room temperature
  2. filtrationis filtered off
  3. customthe filtrate evaporated to a solid foam
  4. customBecause of the lability of this compound, it is used in the next stage without purification

Sources & evidence

ORD record
ord-7fd331b1db794315a62deb9321ba60f9
Source dataset
uspto-grants-1976_03
Patent number
US03944560

Reaction notes

Loading…